Treatment for Type-2-Diabetes News: Fixed Combination of DPP-4 and SGLT-2 Inhibitors

被引：0
|
作者：
不详
机构：
来源：
DIABETES STOFFWECHSEL UND HERZ | 2018年 / 27卷 / 03期
关键词：
TYPE-2; DIABETES-MELLITUS; MILLION PEOPLE; SITAGLIPTIN; THERAPY; RISK;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：157 / 158
页数：2
相关论文
共 50 条
  • [21] Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients
    Alsalim, Wathik
    Persson, Margaretha
    Ahren, Bo
    DIABETES OBESITY & METABOLISM, 2018, 20 (07) : 1652 - 1658
  • [22] The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors
    Secrest, Matthew H.
    Udell, Jacob A.
    Filion, Kristian B.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2017, 27 (03) : 194 - 202
  • [23] Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential
    Mikhail, Nasser
    VASCULAR HEALTH AND RISK MANAGEMENT, 2008, 4 (06) : 1221 - 1227
  • [24] The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands
    van der Linden, N.
    Van Olst, S.
    Nekeman, S.
    Uyl-de Groot, C. A.
    DIABETIC MEDICINE, 2021, 38 (04)
  • [25] Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes
    André J. Scheen
    Clinical Pharmacokinetics, 2017, 56 : 703 - 718
  • [26] The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes
    Choe, Eun Yeong
    Cho, Yongin
    Choi, Younjeong
    Yun, Yujung
    Wang, Hye Jin
    Kwon, Obin
    Lee, Byung-Wan
    Ahn, Chul Woo
    Cha, Bong Soo
    Lee, Hyun Chul
    Kang, Eun Seok
    DIABETES & METABOLISM JOURNAL, 2014, 38 (03) : 211 - 219
  • [27] The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes
    Gillard, Pieter
    Schnell, Oliver
    Groop, Per-Henrik
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2020, 170
  • [28] DPP-4 inhibitors and type 2 diabetes mellitus in Parkinson's disease: a mutual relationship
    Alrouji, Mohammed
    Al-kuraishy, Hayder M.
    Al-buhadily, Ali K.
    Al-Gareeb, Ali I.
    Elekhnawy, Engy
    Batiha, Gaber El-Saber
    PHARMACOLOGICAL REPORTS, 2023, 75 (04) : 923 - 936
  • [29] Hyperkalemia and maintenance of renin-angiotensin system inhibitor therapy after initiating SGLT-2 or DPP-4 inhibitors
    Bosi, Alessandro
    Xu, Yang
    Faucon, Anne-Laure
    Huang, Tao
    Evans, Marie
    Shin, Jung-Im
    Fu, Edouard L.
    Carrero, Juan Jesus
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2025, 40 (05) : 956 - 966
  • [30] The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies
    Molina-Vega, Maria
    Munoz-Garach, Araceli
    Fernandez-Garcia, Jose C.
    Tinahones, Francisco J.
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (08) : 815 - 824
12345